Digital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Teladoc Inc
TDOC
Current price
$7.52
A leader in virtual healthcare, it offers a wide range of services including chronic condition management and mental health support through its digita...
A leader in virtual healthcare, it offers a wide range of services including chronic condition management and mental health support through its digital platform.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Digital therapeutics represent a fundamental shift in healthcare delivery. These clinically-validated software programs are designed to prevent, manage, or treat medical conditions without traditional drugs or devices. As healthcare embraces technology, these scalable solutions promise better patient outcomes at lower costs.
What You Need to Know
This is an emerging, high-growth sector with significant potential but also substantial risk. Insurance reimbursement is the critical catalyst for widespread adoption. Companies range from pure-play digital therapeutics developers to larger telehealth platforms incorporating these technologies into broader offerings.
Why These Stocks
We've selected companies directly involved in creating or delivering software-based medical treatments. This includes dedicated digital therapeutics developers, telehealth platforms enabling digital prescriptions, and companies creating complementary technologies that support this emerging ecosystem.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+219.01%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 219.01% over the next year.
Stocks Rated Buy by Analysts
11 of 14 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Software Is Becoming Medicine
These companies are creating FDA-cleared apps that actually treat diseases. It's a whole new category of medicine where code itself becomes the treatment—potentially reaching millions of patients at a fraction of traditional costs.
Insurance Companies Are Paying Up
The big breakthrough? Insurance providers are increasingly willing to reimburse for these digital therapies. This payment validation could trigger explosive growth as these treatments become mainstream healthcare options.
Early Days of a Healthcare Revolution
We're just at the beginning of software-as-medicine. With chronic diseases, mental health conditions, and preventative care all being targeted, these companies are pioneering what could become a multi-billion dollar healthcare category.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Uncle Sam's Semiconductor Stake
The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.
The Cybersecurity Consolidation Wave
Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.
American Chipmakers: A Tariff-Driven Shift
President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.
Frequently Asked Questions
Everything you need to know about the product and billing.